Sarepta is finally getting some competition
Yesterday, the Japanese drug company NS Pharma won FDA approval for a muscular dystrophy drug that will make for Sarepta Therapeutics’ first competition in the space.
NS’s drug, branded Viltepso, is for the roughly 8% of Duchenne muscular dystrophy patients whose disease stems from a mutation in the DNA sequence known as exon 53. That’s the same population Sarepta targets with Vyondys 53, a treatment approved in September.
The approval of Viltepso serves less as a threat to Sarepta, whose long-term fate is tied to experimental gene therapies, than a reminder of how far the company has come in a year. In August 2019, Sarepta’s share price had fallen from about $150 to $75 after the FDA rejected Vyondys 53’s initial application, setting up a situation in which NS might beat Sarepta to the market. Today, both drugs are approved, and Sarepta trades for $158 a share.
NS’s drug, branded Viltepso, is for the roughly 8% of Duchenne muscular dystrophy patients whose disease stems from a mutation in the DNA sequence known as exon 53. That’s the same population Sarepta targets with Vyondys 53, a treatment approved in September.
The approval of Viltepso serves less as a threat to Sarepta, whose long-term fate is tied to experimental gene therapies, than a reminder of how far the company has come in a year. In August 2019, Sarepta’s share price had fallen from about $150 to $75 after the FDA rejected Vyondys 53’s initial application, setting up a situation in which NS might beat Sarepta to the market. Today, both drugs are approved, and Sarepta trades for $158 a share.
.png)
No hay comentarios:
Publicar un comentario